Journal rankings · indicator year 2008
Choose a field to open its ranking, or a journal to find its row in its subfield’s list.
Subfield ranking · 2008
Oncology journal rankings 2008
127 ranked journals · Subfield in Medicine
Oncology has 127 ranked journals in 2008. The median journal has an OJR of 0.94, below the world average of 1.00, up 0.05 on 2007; Q1 starts at OJR 1.40. The top three are CA A Cancer Journal for Clinicians, Cancer Cell, and Nature Medicine.
Ranks and citation indicators: 2008. Journal access status and listed APC: source snapshot September 23, 2026.
Journals whose main subfield sits in this category and that published at least 30 citable documents (articles, reviews and conference papers) in 2005–2007, the window the 2008 score is computed on.
The OpenJournalRank Indicator (OJR) is a free, publicly available metric of a journal’s field-normalized citation impact, computed from open OpenAlex citation data. It compares citations to a journal’s papers from the previous three years with the world average for papers of the same subfield, year and type, so 1.00 is the world average and values can be compared across fields. It is computed with the NCI3 method.
The middle OJR among ranked journals in this category: half score higher, half lower. 1.00 is the world average for papers of the same subfield, year and type.
The dot is this category, the solid tick is the median of all ranked journals and the dashed line is the world average.
Share of ranked journals in this category that are fully open access, so every paper is free to read. Hybrid journals, which sell subscriptions and open single papers for a fee, are not counted.
Median list price of the article processing charge, in US dollars, among ranked journals in this category that list a price above zero. Journals with a listed APC of $0 and journals with no known price are left out of this median. The At a glance table below gives a second median that includes the $0 prices.
Subfields of Medicine (42)
- Surgery474
- Pulmonary and Respiratory Medicine199
- Cardiology and Cardiovascular Medicine173
- Public Health, Environmental and Occupational Health173
- Oncology127
- Epidemiology114
- Infectious Diseases106
- Psychiatry and Mental health98
- Radiology, Nuclear Medicine and Imaging94
- Endocrinology, Diabetes and Metabolism89
- Physiology89
- Neurology85
Show all 42 subfields
- Orthopedics and Sports Medicine60
- Pediatrics, Perinatology and Child Health60
- Ophthalmology55
- Hematology52
- Dermatology50
- Obstetrics and Gynecology45
- Rheumatology38
- Nephrology33
- Pharmacology32
- Reproductive Medicine32
- Emergency Medicine29
- Complementary and alternative medicine28
- Geriatrics and Gerontology24
- Otorhinolaryngology21
- Pathology and Forensic Medicine18
- Rehabilitation18
- Immunology and Allergy15
- Critical Care and Intensive Care Medicine14
- Genetics11
- Anesthesiology and Pain Medicine9
- Hepatology9
- Urology8
- Gastroenterology7
- Internal Medicine4
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
127 ranked journals
Filters
Rank is the position by OJR within the list on screen; 1 is the highest. | OJR is field-normalized 3-year citation impact: 1.00 is the world average for papers of the same subfield, year and type, so values compare across fields. The badge is the journal’s quartile in this list. | Citations per paper over a two-year window, counted from OpenAlex. It is not field-normalized, so compare it only between journals of the same field. ▲ or ▼ is the change from 2007. This is OpenJournalRank’s own count, not Clarivate’s Journal Impact Factor. | Citable documents (articles, reviews and conference papers) published in 2005–2007, the window the 2008 OJR is computed on. A journal needs at least 30 to be ranked. | Share of the journal’s 2005–2007 papers that are free to read in any open-access form. The green OA tag next to a title marks a fully open-access journal. | List price of the article processing charge in US dollars. “$0 listed” means the listed price is zero; a dash means no price is listed. | The line is the journal’s OJR from 2000 to 2008. | Compare |
|---|---|---|---|---|---|---|---|
1CA A Cancer Journal for CliniciansOAWiley · United States | 42.32Q1 | 81.86 4.59 down from 2007 | 63 | 100% | $4,330 | ||
2Cancer CellCell Press · Netherlands | 6.84Q1 | 18.74 0.79 up from 2007 | 372 | 99% | $10,400 | ||
3Nature MedicineNature Portfolio · United States | 5.08Q1 | 12.21 1.74 up from 2007 | 1,218 | 28% | $12,690 | ||
4Journal of Clinical OncologyLippincott Williams & Wilkins · United States | 5.01Q1 | 12.16 0.11 down from 2007 | 3,368 | 13% | — | ||
5JNCI Journal of the National Cancer InstituteOxford University Press · United States | 4.71Q1 | 11.54 0.47 down from 2007 | 738 | 48% | $5,436 | ||
6The Lancet OncologyElsevier BV · United Kingdom | 3.43Q1 | 8.30 0.48 up from 2007 | 535 | 10% | $7,280 | ||
7Clinical Pharmacology & TherapeuticsWiley · United States | 3.27Q1 | 5.76 0.11 down from 2007 | 708 | 16% | $4,410 | ||
8The OncologistOAAlphaMed Press · United Kingdom | 2.99Q1 | 7.80 2.26 up from 2007 | 421 | 66% | $3,852 | ||
9Seminars in Cancer BiologyElsevier BV · United States | 2.91Q1 | 7.59 0.02 up from 2007 | 160 | 35% | $6,060 | ||
10Clinical Cancer ResearchAmerican Association for Cancer Research · United States | 2.59Q1 | 6.71 0.15 up from 2007 | 3,362 | 43% | — | ||
11CancerWiley · United States | 2.48Q1 | 5.74 0.62 up from 2007 | 2,423 | 68% | $4,790 | ||
12Critical Reviews in Oncology/HematologyElsevier BV · Netherlands | 2.19Q1 | 5.36 0.13 up from 2007 | 275 | 4% | $4,190 | ||
13Molecular Cancer TherapeuticsAmerican Association for Cancer Research · United States | 2.12Q1 | 5.63 0.50 up from 2007 | 948 | 54% | — | ||
14Annals of OncologyElsevier BV · Netherlands | 2.08Q1 | 4.86 0.23 up from 2007 | 1,443 | 97% | $5,080 | ||
15European Journal of CancerElsevier BV · United Kingdom | 2.08Q1 | 5.31 0.35 up from 2007 | 1,065 | 16% | $4,270 | ||
16JNCI MonographsOxford University Press · United Kingdom | 2.07Q1 | 2.42 2.07 down from 2007 | 73 | 83% | — | ||
17Cancer Epidemiology Biomarkers & PreventionAmerican Association for Cancer Research · United States | 1.98Q1 | 5.02 0.06 down from 2007 | 1,420 | 59% | — | ||
18British Journal of CancerSpringer Nature · United Kingdom | 1.97Q1 | 5.47 0.21 up from 2007 | 1,704 | 100% | $5,190 | ||
19Cancer ControlOASAGE Publishing · United States | 1.96Q1 | 4.26 1.03 up from 2007 | 134 | 40% | $2,650 | ||
20Journal of Mammary Gland Biology and NeoplasiaSpringer Science+Business Media · United States | 1.89Q1 | 4.56 0.25 up from 2007 | 84 | 26% | $4,090 | ||
21Psycho-OncologyWiley · United Kingdom | 1.86Q1 | 2.76 0.08 down from 2007 | 366 | 29% | $4,940 | ||
22Current Opinion in OncologyLippincott Williams & Wilkins · United Kingdom | 1.86Q1 | 4.45 0.77 up from 2007 | 237 | 10% | — | ||
23International Journal of CancerWiley · United States | 1.82Q1 | 4.88 0.33 up from 2007 | 2,407 | 69% | $5,030 | ||
24Integrative Cancer TherapiesOASAGE Publishing · United States | 1.70Q1 | 2.68 0.29 up from 2007 | 121 | 100% | $2,650 | ||
25Seminars in OncologyElsevier BV · United States | 1.70Q1 | 5.11 1.30 up from 2007 | 390 | 13% | $3,550 | ||
26Expert Opinion on Investigational DrugsTaylor & Francis · United Kingdom | 1.69Q1 | 4.13 0.22 up from 2007 | 447 | 7% | — | ||
27Diseases of the Colon & RectumLippincott Williams & Wilkins · United States | 1.64Q1 | 3.33 0.09 down from 2007 | 860 | 6% | — | ||
28Cancer Causes & ControlSpringer Science+Business Media · Netherlands | 1.64Q1 | 4.11 0.13 down from 2007 | 438 | 45% | $3,890 | ||
29Journal of the National Comprehensive Cancer NetworkNational Comprehensive Cancer | 1.54Q1 | 3.26 0.54 up from 2007 | 144 | 57% | — | ||
30JBIC Journal of Biological Inorganic ChemistrySpringer Science+Business Media · Germany | 1.53Q1 | 3.39 0.18 up from 2007 | 363 | 32% | $3,990 | ||
31MicrocirculationWiley · United States | 1.41Q1 | 3.33 0.03 down from 2007 | 164 | 38% | $3,920 | ||
32Journal of ImmunotherapyLippincott Williams & Wilkins · United States | 1.40Q1 | 4.41 0.78 down from 2007 | 210 | 21% | — | ||
33BMC CancerOABioMed Central · United Kingdom | 1.37Q2 | 3.70 0.22 up from 2007 | 695 | 100% | $3,390 | ||
34Investigational New DrugsSpringer Science+Business Media · Netherlands | 1.36Q2 | 3.26 0.35 up from 2007 | 226 | 14% | $4,690 | ||
35European Journal of EpidemiologySpringer Science+Business Media · Italy | 1.35Q2 | 2.87 0.70 up from 2007 | 396 | 15% | $3,690 | ||
36Cancer Treatment ReviewsElsevier BV · United Kingdom | 1.35Q2 | 4.89 0.81 up from 2007 | 230 | 4% | $4,910 | ||
37Journal of Inorganic BiochemistryElsevier BV · United States | 1.33Q2 | 3.18 0.09 down from 2007 | 755 | 16% | $4,220 | ||
38Supportive Care in CancerSpringer Science+Business Media · Germany | 1.33Q2 | 2.85 0.47 up from 2007 | 486 | 15% | $4,690 | ||
39Cancer NursingLippincott Williams & Wilkins · United States | 1.31Q2 | 2.25 0.09 down from 2007 | 210 | 9% | — | ||
40CytotherapyElsevier BV · United Kingdom | 1.30Q2 | 3.64 0.11 up from 2007 | 225 | 9% | $3,300 | ||
41Journal of Surgical OncologyWiley · United States | 1.26Q2 | 2.44 0.26 down from 2007 | 707 | 9% | $4,570 | ||
42Clinical & Experimental MetastasisSpringer Science+Business Media · Netherlands | 1.26Q2 | 3.46 0.53 up from 2007 | 205 | 26% | $5,090 | ||
43The Cancer JournalLippincott Williams & Wilkins · United States | 1.25Q2 | 3.04 0.97 up from 2007 | 186 | 8% | — | ||
44Hematology/Oncology Clinics of North AmericaElsevier BV · United States | 1.25Q2 | 2.90 0.90 up from 2007 | 207 | 6% | $3,950 | ||
45Current Treatment Options in OncologySpringer Science+Business Media · United States | 1.24Q2 | 3.30 0.27 up from 2007 | 135 | 8% | $4,890 | ||
46OncologyKarger Publishers · Switzerland | 1.18Q2 | 2.17 0.65 down from 2007 | 433 | 17% | — | ||
47Journal of Clinical PathologyBMJ · United Kingdom | 1.16Q2 | 2.58 0.11 up from 2007 | 959 | 10% | — | ||
48European Journal of Oncology NursingElsevier BV · United Kingdom | 1.13Q2 | 2.00 0.65 up from 2007 | 136 | 17% | $3,790 | ||
49Breast Cancer ResearchOABioMed Central · United Kingdom | 1.12Q2 | 3.92 1.22 up from 2007 | 730 | 100% | $4,190 | ||
50Cancer Immunology ImmunotherapyOASpringer Science+Business Media · Germany | 1.12Q2 | 3.58 0.04 down from 2007 | 495 | 100% | $4,590 |
Subfields of Medicine, with Oncology highlighted.
- Surgery474
- Pulmonary and Respiratory Medicine199
- Cardiology and Cardiovascular Medicine173
- Public Health, Environmental and Occupational Health173
- Oncology127
- Epidemiology114
- Infectious Diseases106
- Psychiatry and Mental health98
- Radiology, Nuclear Medicine and Imaging94
- Endocrinology, Diabetes and Metabolism89
- Physiology89
- Neurology85
- Orthopedics and Sports Medicine60
- Pediatrics, Perinatology and Child Health60
- Ophthalmology55
- Hematology52
- Dermatology50
- Obstetrics and Gynecology45
- Rheumatology38
- Nephrology33
- Pharmacology32
- Reproductive Medicine32
- Emergency Medicine29
- Complementary and alternative medicine28
- Geriatrics and Gerontology24
- Otorhinolaryngology21
- Pathology and Forensic Medicine18
- Rehabilitation18
- Immunology and Allergy15
- Critical Care and Intensive Care Medicine14
- Genetics11
- Anesthesiology and Pain Medicine9
- Hepatology9
- Urology8
- Gastroenterology7
- Internal Medicine4
- Transplantation2
- Biochemistry1
- Family Practice1
- Anatomy0
- Health Informatics0
- Microbiology0
Journals
Citations made in 2008. Corpus-wide, 71.1% of core-journal articles and reviews published that year have at least one matched reference; the share varies by journal and field.
42 additional Oncology journals with metrics are unranked under this release’s eligibility rules: a journal needs at least 30 citable documents in 2005–2007, at least 80% of them with a subfield, and a positive world-average expectation. Ranks are within the whole category; filters hide rows without re-ranking. OJR excludes self-citations.
At a glance
Indicator year: 2008. Publication window: 2005–2007. How these summaries are calculated
- Ranked journals
- 127
- Window papers (baseline)
- 66,087 +24.4% from indicator year 2005
- Median OJR
- 0.94 +13.6% from indicator year 2005
- Rising journals (2025)
- 20
Window papers are the baseline paper population: citable papers (articles, reviews and conference papers) from 2005–2007 in all journals of the world-average baseline, including non-core journals, counted by each paper’s own subfield. They are not the papers of the ranked journals alone.
| Measure | Year series | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ranked journals | 82 | 88 | 96 | 103 | 109 | 120 | 120 | 126 | 127 | 134 | 141 | 150 | 153 | 170 | 179 | 188 | 198 | 213 | 224 | 234 | 238 | 239 | 245 | 245 | 243 | 242 | |
| Window papers (baseline) | 37,821 | 41,430 | 44,340 | 47,392 | 49,058 | 53,111 | 57,002 | 62,106 | 66,087 | 71,283 | 77,009 | 82,075 | 86,189 | 88,804 | 93,912 | 98,660 | 102,921 | 105,891 | 109,984 | 115,044 | 121,890 | 139,666 | 156,942 | 167,602 | 163,907 | 160,807 | |
| Median OJR | 0.55 | 0.62 | 0.70 | 0.799 | 0.805 | 0.831 | 0.85 | 0.90 | 0.94 | 0.93 | 1.010 | 0.95 | 1.006 | 0.974 | 0.972 | 0.967 | 0.832 | 0.84 | 0.82 | 0.79 | 0.829 | 0.830 | 0.77 | 0.750 | 0.73 | 0.748 |
How to read these rankings
- OJR, the OpenJournalRank Indicator
- A field-normalized 3-year citation impact, computed from OpenAlex with the NCI3 method. It divides the citations a journal’s papers received by the world average for papers of the same subfield, year and type, so 1.00 is the world average and 2.00 means twice as many citations as expected. Because it is normalized, it can be compared across fields. Read the methodology
- Quartiles
- Q1 to Q4 split the ranked journals of the list you are viewing into four equal groups by OJR. A journal’s quartile depends on the list: the same journal can be Q1 in its subfield and Q2 among all journals.
- Impact factor (2-year)
- Citations per paper over a two-year window, counted from OpenAlex. It is easy to compare with familiar impact factors but is not field-normalized, so compare it only within a field. It is not Clarivate’s Journal Impact Factor. Why it differs from the Journal Impact Factor
- Rank ranges
- Each rank in the latest year carries a likely range from 1,000 resamples of the journal’s papers. Where two journals’ ranges overlap, the data cannot tell them apart, so treat neighbouring ranks as ties.